Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

bone marrow cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Antibiotic (1) Apoptosis (6) Autophagy (1) Bacterial (2) Bcl-2 Family (1) c-Fms (3) CD73 (1) CXCR (2) Endogenous Metabolite (1) Fat Mass and Obesity-associated Protein (FTO) (1) Fluorescent Dye (1) GPR84 (1) HDAC (1) Histamine Receptor (1) HIV (1) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (1) MDM-2/p53 (1) Microtubule/Tubulin (1) NF-κB (4) NOD-like Receptor (NLR) (1) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (1) Parasite (2) Phosphodiesterase (PDE) (4) PPAR (1) Progesterone Receptor (1) Reactive Oxygen Species (1) STING (1) TGF-β Receptor (1)
By Research Areas:	Cancer (24) Cardiovascular Disease (5) Endocrinology (3) Infection (6) Inflammation/Immunology (12) Metabolic Disease (3) Neurological Disease (3)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1403

Tigogenin	Others	Metabolic Disease
Tigogenin, one of steroidal sapogenins, is widely used for synthesizing steroid agents. Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells .

HY-147011

FTO-IN-7	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO-IN-7 is an inhibitor of FTO. FTO-IN-7 can be used in study Alzheimer's diseases, breast cancers, small-cell lung cancers,a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma .

HY-W088068

Wright's stain	Fluorescent Dye	Others
Wright's stain is a hematologic stain that facilitates the differentiation of blood cell types. Wright's stain is classically a mixture of eosin (red) and methylene blue dyes. It is used primarily to stain peripheral blood smears, urine samples, and bone marrow aspirates. Wright's stain provides a manual or automated stain for bone marrow and peripheral blood smears .

HY-126346

DL-175	GPR84	Inflammation/Immunology
DL-175 (compound 13) is a selective GPR84 agonist with biased agonistic activity. DL-175 can selectively activate functional responses in immune cells and induce enhanced chemotaxis and phagocytosis of human bone marrow cells. DL-175 is a potential chemical probe .

HY-P3736

Myelopeptide-2 MP-2	Interleukin Related	Cancer
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research .

HY-N4019

Maohuoside A	TGF-β Receptor	Metabolic Disease
Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways .

HY-117365

MI-1481	Others	Cancer
MI-1481 is a highly potent inhibitor of the Menin-MLL1 interaction with IC₅₀ of 3.6 nM. MI-1481 markedly reduces cell growth of murine bone marrow cells transformed and inhibits leukemia progression .

HY-N3646

Cudratricusxanthone A	Others	Others Neurological Disease Inflammation/Immunology Cancer
Cudratricusxanthone A is isolated from Cudrania tricuspidata, and has anti-inflammatory, hepatoprotective, and anti-proliferative activities. Cudratricusxanthone A inhibits osteoclast differentiation and function in RAW 264.7 cells and mouse bone marrow monocytes .

HY-160696

ORIC-533	CD73	Cancer
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .

HY-134259

MEISi-2	Others	Cancer
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .

HY-N3316

Martynoside	Others
Martynoside protects ex vivo bone marrow cells from 5-fluorouracil (5-FU)-induced cell death and inflammation response by down-regulating the TNF signaling pathway .Martynoside is a potent antiestrogen in MCF-7 cells, increasing IGFBP3 levels

HY-N12507

Eupenicisirenin C	STING NF-κB	Others
Eupenicisirenin C (compound 1) is a sirenin derivative. Eupenicisirenin C has strong NF-κB inhibitory activities. Eupenicisirenin C suppresses effects on cGAS-STING pathway. Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage cells .

HY-125911

Gossypin	NF-κB	Cardiovascular Disease Inflammation/Immunology Cancer
Gossypin is a flavone isolated from Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits RANKL-induced osteoclastogenesis both in mouse primary bone marrow cells and RAW 264.7 cells in vitro .

HY-N0012

Glycitin Glycitein 7-O-β-glucoside	Bacterial	Infection Cancer
Glycitin (Glycitein 7-O-β-glucoside) is a natural isoflavone with antibacterial, antiviral, anticancer, anti-inflammation, anti-aging and estrogenic effects. Glycitin may regulate osteoblasts through TGF-β or AKT signaling pathways in bone marrow stem cells (BMSCs) .

HY-162346

KN-17	Bacterial	Infection
KN-17 is a modified based on the structure of cecropin B (HY-P0092), can effectively interfere with bacterial growth and induce the migration of human bone marrow stromal cells (hBMSCs). KN-17 can significantly stimulate angiogenesis in vitro and in vivo .

HY-147511

PPARγ agonist 7	PPAR	Others
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of PPARγ. PPARγ agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC₅₀, 4.34 μM) .

HY-P99536

Tagraxofusp SL-401	Interleukin Related	Cancer
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .

HY-W795264

FR900098	Parasite	Infection
FR900098 is an antimalarial agent that inhibits 1-deoxy-d-xylulose-5-phosphate (DXP) reductoisomerase. FR900098 has no significant acute toxicity or genotoxicity, and does not have the ability to cause chromosome breakage or heterogeneity. FR900098 has no effect on bone marrow red blood cells in NMRI mice .

HY-122817

FR900098 sodium	Antibiotic Parasite	Infection
FR900098 sodium is an antimalarial agent that inhibits 1-deoxy-d-xylulose-5-phosphate (DXP) reductoisomerase. FR900098 sodium has no significant acute toxicity or genotoxicity, and does not have the ability to cause chromosome breakage or heterogeneity. FR900098 sodium has no effect on bone marrow red blood cells in NMRI mice .

HY-N0307

Ciwujianoside B	Bcl-2 Family	Neurological Disease
Ciwujianoside B is isolated from Eleutherococcus senticosus leaf, is able to penetrate and work in the brain after the oral administration. Ciwujianoside B significantly enhances object recognition memory . Ciwujianoside B shows radioprotective effects on the hematopoietic system in mice, which is associated with changes in the cell cycle, reduces DNA damage and down-regulates the ratio of Bax/Bcl-2 in bone marrow cells exposed to radiation .

HY-108694

γ-Tocotrienol 1 Publications Verification	Endogenous Metabolite NF-κB	Metabolic Disease Inflammation/Immunology
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .

HY-B0523

Anagrelide	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-B0523B

Anagrelide hydrochloride monohydrate	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide hydrochloride monohydrate is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride monohydrate, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride monohydrate inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride monohydrate decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride monohydrate is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-B0111

Drospirenone Dihydrospirorenone	Progesterone Receptor Androgen Receptor	Endocrinology Cancer
Drospirenone (Dihydrospirorenone) is an orally active fourth-generation progestin that interacts with the progesterone receptor (PR) and androgen receptor (AR). Drospirenone significantly decreases both plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) via the AR. Drospirenone can produce DNA damage in bone marrow cells of female mice. .

HY-B0523A

Anagrelide hydrochloride 2 Publications Verification BL4162A	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-W018643

Ferulic acid methyl ester Methyl ferulate	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology Cancer
Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties . Ferulic acid methyl ester is a cell membrane and brain permeable compound, shows free radical scavenging ability, used in the research of neurodegenerative disorders . Ferulic acid methyl ester inhibits COX-2 expression, blocks p-p38 and p-JNK in primary bone marrow derived-macrophages .

HY-118452

cis-3,4',5-Trimethoxy-3'-hydroxystilbene	Microtubule/Tubulin Apoptosis	Cancer
cis-3,4',5-Trimethoxy-3'-hydroxystilbene is a stilbene. cis-3,4',5-Trimethoxy-3'-hydroxystilbene induces cytochrome c release to the cytoplasm. cis-3,4',5-Trimethoxy-3'-hydroxystilbene-induced apoptosis is associated with mitochondrial release of cytochrome c. cis-3,4',5-Trimethoxy-3'-hydroxystilbene also suppresses tubulin polymerization. cis-3,4',5-Trimethoxy-3'-hydroxystilbene can be used for leukemic research .

HY-160214

Perforin-IN-2	Others	Inflammation/Immunology
Perforin-IN-2 is a benzosulfonamide perforin inhibitor that alleviates transplant rejection during allogeneic bone marrow/stem cell transplantation. Perforin-IN-2 binds to plasma proteins with a binding rate of 99.8%. Perforin-IN-2 requires a higher concentration (> 900 μM) to achieve optimal perforin inhibition in vivo. Perforin-in-2 can effectively inhibit the lytic activity of recombinant perforin on Jurkat T (IC₅₀=6.65 μM) leukemia cells, and also inhibit the death of K562 leukemia target cells .

HY-151569

SAHA-OH	HDAC Apoptosis	Inflammation/Immunology
SAHA-OH is a selective HDAC6 inhibitor (IC₅₀=23 nM), shows a 10- to 47-fold selectivity for HDAC6 compared to HDAC 1, 2, 3, and 8. SAHA-OH shows anti-inflammatory activity, and attenuates macrophage apoptosis .

HY-147615

CSF1R-IN-12	c-Fms	Cancer
CSF1R-IN-12 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) .

HY-147616

CSF1R-IN-13	c-Fms	Cancer
CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .

HY-131040

NLRP3-IN-NBC6	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC₅₀= 574 nM) that acts independently of Ca ²⁺. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .

HY-136214

R-BC154 acetate	Integrin	Inflammation/Immunology Cancer
R-BC154 acetate is a selective fluorescent α₉β₁ integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity .

HY-P0172A

ATI-2341 TFA 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P0172

ATI-2341	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-B0523S

Anagrelide-13C2,15N,d2	Apoptosis Phosphodiesterase (PDE) Isotope-Labeled Compounds	Cardiovascular Disease Cancer
Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36?nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-147617

CSF1R-IN-14	c-Fms	Cancer
CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) .

HY-106850

3′-Azido-2′,3′-dideoxyuridine AzdU; AzddU; CS-87	HIV	Infection
3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-113790

ISX-1

Others Others

ISX-1 is an isoxazole. ISX-1 has anti-adipogenic and pro-osteogenic activities. ISX-1 can be used for the research of osteopenia and osteoporosis .

ISX-1	Others	Others
ISX-1 is an isoxazole. ISX-1 has anti-adipogenic and pro-osteogenic activities. ISX-1 can be used for the research of osteopenia and osteoporosis .

HY-117987

CPS-11 N-(Hydroxymethyl)thalidomide	Nuclear Factor of activated T Cells (NFAT) NF-κB Reactive Oxygen Species	Cancer
CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines .

HY-101188

INCB38579	Histamine Receptor	Infection
INCB38579 is an orally active, highly brain penetrable, and selective histamine H₄ receptor (HH₄R) antagonist (hH₄R IC₅₀=4.8 nM, mH₄R IC₅₀=42 nM, rH₄R IC₅₀=32 nM). INCB38579 shows anti-inflammatory pain and anti-pruritic activities .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library	2706 Compounds compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 2706 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

2706 Compounds compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 2706 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L174

Macrophage Related Compound Library	153 compounds
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 153 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Macrophage Related Compound Library

153 compounds

Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.

MCE designs a unique collection of 153 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

HY-L079

Anti-Blood Cancer Compound Library	2676 compounds
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Anti-Blood Cancer Compound Library

2676 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Cat. No.	Product Name	Type